Monthly Archives: February 2021

Immune checkpoint inhibitor (ICPI)-mediated diarrhea and colitis is the leading cause of discontinuation of ICPI therapy in patients with malignancy. Existing literature on predictors of adverse outcomes is limited. We evaluated the association between… Continue reading →

Chronic granulomatous disease (CGD) is a rare immunodeficiency caused by mutations in the NADPH oxidase complex. Dysregulated immune function may cause inflammatory bowel disease (IBD). Patients with CGD-associated IBD may not respond to or may develop… Continue reading →

Macrophages are essential immune cells for the maintenance of tissue homeostasis in the intestinal mucosa barrier. They are also involved in dysregulated process of wound healing, particularly in the context of intestinal damage and tissue repair in in… Continue reading →

The change in subclassification of inflammatory bowel diseases (IBD) among patients with Crohn’s (CD), ulcerative colitis (UC), and IBD-unclassified (IBD-u) has previously been described in subpopulations of adult and pediatric patients. To date, no la… Continue reading →

Ulcerative colitis (UC) is a progressive disorder that elevates the risk of cancer development through a colitis-dysplasia-carcinoma sequence. Recent evidence demonstrates the necessity of Hippo-YAP/TAZ signaling, interceded by cytoskeletal remodeling,… Continue reading →

As the Coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to evolve, its influence on specific patient populations suffering from chronic disorders becomes increasingly im… Continue reading →

Long-term persistence of chronic inflammation in inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn’s disease (CD) is among the major factors contributing to neoplastic transformation and the development of colitis-associated … Continue reading →

The prevalence of inflammatory bowel disease (IBD) is increasing throughout the developed world. For the newly diagnosed, the time between the appearance of symptoms and diagnosis can take months, involving invasive procedures. There is an urgent need … Continue reading →

There is a growing need for biomarkers of inflammation to monitor and predict therapeutic outcome in Crohn’s disease (CD) patients. We aimed to evaluate whether the level of circulating blood cells, expressed as ratios (NLR, neutrophil-to-lymphocyte ra… Continue reading →

To evaluate the safety profile of amiselimod, a selective sphingosine 1-phosphate receptor modulator which has been shown to regulate lymphocyte trafficking and is in development for the treatment of inflammatory bowel disease. Continue reading →